Increased intratumoral androgens in human breast carcinoma following aromatase inhibitor exemestane treatment

Endocrine-Related Cancer

Volumn 17, Issue 2, 2010, Pages 415-430

  Takagi, Kiyoshi ^a   Miki, Yasuhiro ^a   Nagasaki, Shuji ^a   Hirakawa, Hisashi ^b   Onodera, Yoshiaki ^a   Akahira, Jun Ichi ^a   Ishida, Takanori ^a   Watanabe, Mika ^c   Kimijima, Izo ^d   Hayashi, Shin Ichi ^a   Sasano, Hironobu ^a   Suzuki, Takashi ^a  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b TOHOKU ROSAI HOSPITAL   (Japan)

^c TOHOKU UNIVERSITY HOSPITAL   (Japan)

^d FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROSTANOLONE; ESTRADIOL; EXEMESTANE; TESTOSTERONE 17BETA DEHYDROGENASE; TESTOSTERONE 17BETA DEHYDROGENASE 2; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOLOCALIZATION; NUCLEOTIDE SEQUENCE; UPREGULATION;

AGED; ANDROGENS; ANDROSTADIENES; AROMATASE INHIBITORS; BLOTTING, WESTERN; BREAST; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CELL LINE, TUMOR; CELL PROLIFERATION; CELLS, CULTURED; CHROMATOGRAPHY, LIQUID; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MICROARRAY ANALYSIS; MIDDLE AGED; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TANDEM MASS SPECTROMETRY;

EID: 77953605636     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1677/ERC-09-0257     Document Type: Article

References (48)

1. Adams JB, Pewnim T, Chandra DP, Archibald L & Foo MS 1979 A correlation between estrogen sulfotransferase levels and estrogen receptor status in human primary breast carcinoma. Cancer Research 39 5124-5126. (Pubitemid 10163126)
2. Allred DC, Harvey JM, Berardo M & Clark GM 1998 Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Modern Pathology 11 155-168. (Pubitemid 28144151)
3. Baum M 2004 Current status of aromatase inhibitors in the management of breast cancer and critique of the NCIC MA-17 trial. Cancer Control 11 217-221. (Pubitemid 38970622)
4. Casey ML, MacDonald PC & Andersson S 1994 17beta- Hydroxysteroid dehydrogenase type 2: chromosomal assignment and progestin regulation of gene expression in human endometrium. Journal of Clinical Investigation 94 2135-2141. (Pubitemid 2150103)
5. Cleton-Jansen AM, Callen DF, Seshadri R, Goldup S, Mccallum B, Crawford J, Powell JA, Settasatian C, van Beerendonk H, Moerland EW et al. 2001 Loss of heterozygosity mapping at chromosome arm 16q in 712 breast tumors reveals factors that influence delineation of candidate regions. Cancer Research 61 1171-1177.
6. Coombes RC, Hall E, Gibson LJ, Paridaens R, Jassem J, Delozier T, Jones SE, Alvarez I, Bertelli G, Ortmann O et al. 2004 A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. New England Journal of Medicine 350 1081-1092. (Pubitemid 38298988)
7. Dowsett M, Ebbs SR, Dixon JM, Skene A, Griffith C, Boeddinghaus I, Salter J, Detre S, Hills M, Ashley S et al. 2005a Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination: influence of hormonal status and HER-2 in breast cancer-a study from the IMPACT trialists. Journal of Clinical Oncology 23 2477-2492.
8. Dowsett M, Smith IE, Ebbs SR, Dixon JM, Skene A, Griffith C, Boeddinghaus I, Salter J, Detre S, Hills M et al. 2005b Short-term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival. Clinical Cancer Research 11 951s-958s.
9. Ellis MJ, Coop A, Singh B, Tao Y, Llombart-Cussac A, Jänicke F, Mauriac L, Quebe-Fehling E, Chaudri-Ross HA, Evans DB et al. 2003 Letrozole inhibits tumor proliferation more effectively than tamoxifen independent of HER1/2 expression status. Cancer Research 63 6523-6531. (Pubitemid 37255206)
10. Evans TR, Rowlands MG, Law M & Coombes RC 1994 Intratumoral oestrone sulphatase activity as a prognostic marker in human breast carcinoma. British Journal of Cancer 69 555-561. (Pubitemid 24076479)
11. Geisler J, Detre S, Berntsen H, Ottestad L, Lindtjørn B, Dowsett M & Einstein Lønning P 2001 Influence of neoadjuvant anastrozole (Arimidex) on intratumoral estrogen levels and proliferation markers in patients with locally advanced breast cancer. Clinical Cancer Research 7 1230-1236. (Pubitemid 32708674)
12. Geisler J, Helle H, Ekse D, Duong NK, Evans D & Lønning PE 2006 Letrozole (Femara) causes potent suppression of breast cancer tissue estrogen levels in the neoadjuvant setting. Journal of Clinical Oncology Supplement 24 10532.
13. Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Tu D, Shepherd LE, Pritchard KI et al. 2003 A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. New England Journal of Medicine 349 1793-1802.
14. Greeve MA, Allan RK, Harvey JM & Bentel JM 2004 Inhibition of MCF-7 breast cancer cell proliferation by 5alpha-dihydrotestosterone; a role for p21(Cip1/Waf1). Journal of Molecular Endocrinology 32 793-810.
15. Gunnarsson C, Olsson BM & Stål O 2001 Abnormal expression of 17beta-hydroxysteroid dehydrogenases in breast cancer predicts late recurrence. Cancer Research 61 8448-8451. (Pubitemid 33131123)
16. Gunnarsson C, Hellqvist E & Stål O 2005 17beta- Hydroxysteroid dehydrogenases involved in local oestrogen synthesis have prognostic significance in breast cancer. British Journal of Cancer 92 547-552.
17. Han B, Li S, Song D, Poisson-Pare D, Liu G, Luu-The V, Ouellet J, Li S, Labrie F & Pelletier G 2008 Expression of 17beta-hydroxysteroid dehydrogenase type 2 and type 5 in breast cancer and adjacent non-malignant tissue: a correlation to clinicopathological parameters. Journal of Steroid Biochemistry and Molecular Biology 112 194-200.
18. Howell A, Cuzick J, Baum M, Buzdar A, Dowsett M, Forbes JF, Hoctin-Boes G, Houghton J, Locker GY & Tobias JS 2005 Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 365 60-62.
19. Kannan K, Amariglio N, Rechavi G, Jakob-Hirsch J, Kela I, Kaminski N, Getz G, Domany E & Givol D 2001 DNA microarrays identification of primary and secondary target genes regulated by p53. Oncogene 20 2225-2234.
20. Lanzino M, De Amicis F, McPhaul MJ, Marsico S, Panno ML & Andò S 2005 Endogenous coactivator ARA70 interacts with estrogen receptor alpha (ERalpha) and modulates the functional ERalpha/androgen receptor interplay in MCF-7 cells. Journal of Biological Chemistry 280 20421-20430.
21. Lapointe J & Labrie C 2001 Role of the cyclin-dependent kinase inhibitor p27(Kip1) in androgen-induced inhibition of CAMA-1 breast cancer cell proliferation. Endocrinology 142 4331-4338.
22. Lee YF, Lin WJ, Huang J, Messing EM, Chan FL, Wilding G & Chang C 2002 Activation of mitogen-activated protein kinase pathway by the antiandrogen hydroxyflutamide in androgen receptor-negative prostate cancer cells. Cancer Research 62 6039-6044. (Pubitemid 35244450)
23. Miettinen M, Mustonen M, Poutanen M, Isomaa V, Wickman M, Söderqvist G, Vihko R & Vihko P 1999 17beta- Hydroxysteroid dehydrogenases in normal human mammary epithelial cells and breast tissue. Breast Cancer Research and Treatment 57 175-182.
24. Migliaccio A, Castoria G, Di Domenico M, de Falco A, Bilancio A, Lombardi M, Barone MV, Ametrano D, Zannini MS, Abbondanza C et al. 2000 Steroid-induced androgen receptor-oestradiol receptor beta-Src complex triggers prostate cancer cell proliferation. EMBO Journal 19 5406-5417.
25. Miki Y, Suzuki T, Tazawa C, Yamaguchi Y, Kitada K, Honma S, Moriya T, Hirakawa H, Evans DB, Hayashi S et al. 2007 Aromatase localization in human breast cancer tissues: possible interactions between intratumoral stromal and parenchymal cells. Cancer Research 67 3945-3954.
26. Miller WR & Dixon JM 2002 Endocrine and clinical endpoints of exemestane as neoadjuvant therapy. Cancer Control 9 9-15. (Pubitemid 34457336)
27. Mistry P, Griffiths K & Maynard PV 1986 Endogenous C19-steroids and oestradiol levels in human primary breast tumour tissues and their correlation with androgen and oestrogen receptors. Journal of Steroid Biochemistry 24 1117-1125.
28. Olson JA Jr, Budd GT, Carey LA, Harris LA, Esserman LJ, Fleming GF, Marcom PK, Leight GS Jr, Giuntoli T, Commean P et al. 2009 Improved surgical outcomes for breast cancer patients receiving neoadjuvant aromatase inhibitor therapy: results from a multicenter phase II trial. Journal of the American College of Surgeons 208 906-914.
29. Ortmann J, Prifti S, Bohlmann MK, Rehberger-Schneider S, Strowitzki T & Rabe T 2002 Testosterone and 5alpha-dihydrotestosterone inhibit in vitro growth of human breast cancer cell lines. Gynecological Endocrinology 16 113-120. (Pubitemid 34496877)
30. Panet-Raymond V, Gottlieb B, Beitel LK, Pinsky L & Trifiro MA 2000 Interactions between androgen and estrogen receptors and the effects on their transactivational properties. Molecular and Cellular Endocrinology 167 139-150.
31. Penning TM, Steckelbroeck S, Bauman DR, Miller MW, Jin Y, Peehl DM, Fung KM & Lin HK 2006 Aldo-keto reductase (AKR) 1C3: role in prostate disease and the development of specific inhibitors. Molecular and Cellular Endocrinology 248 182-191.
32. Poulin R, Baker D & Labrie F 1988 Androgens inhibit basal and estrogen-induced cell proliferation in the ZR-75-1 human breast cancer cell line. Breast Cancer Research and Treatment 12 213-225.
33. Recchione C, Venturelli E, Manzari A, Cavalleri A, Martinetti A & Secreto G 1995 Testosterone, dihydro-testosterone and oestradiol levels in postmenopausal breast cancer tissues. Journal of Steroid Biochemistry and Molecular Biology 52 541-546.
34. Saji S, Okumura N, Eguchi H, Nakashima S, Suzuki A, Toi M, Nozawa Y, Saji S & Hayashi S 2001 MDM2 enhances the function of estrogen receptor alpha in human breast cancer cells. Biochemical and Biophysical Research Communications 281 259-265.
35. Sakamoto T, Eguchi H, Omoto Y, Ayabe T, Mori H & Hayashi S 2002 Estrogen receptor-mediated effects of tamoxifen on human endometrial cancer cells. Molecular and Cellular Endocrinology 192 93-104.
36. Shibuya R, Suzuki T, Miki Y, Yoshida K, Moriya T, Ono K, Akahira J, Ishida T, Hirakawa H, Evans DB et al. 2008 Intratumoral concentration of sex steroids and expression of sex steroid-producing enzymes in ductal carcinoma in situ of human breast. Endocrine-Related Cancer 15 113-124.
37. Silva MC, Rowlands MG, Dowsett M, Gusterson B, McKinna JA, Fryatt I & Coombes RC 1989 Intratumoral aromatase as a prognostic factor in human breast carcinoma. Cancer Research 49 2588-2591. (Pubitemid 19143382)
38. Somboonporn W & Davis SR 2004 Postmenopausal testosterone therapy and breast cancer risk. Maturitas 49 267-275.
39. Sonne-Hansen K & Lykkesfeldt AE 2005 Endogenous aromatization of testosterone results in growth stimulation of the human MCF-7 breast cancer cell line. Journal of Steroid Biochemistry and Molecular Biology 93 25-34.
40. Speirs V, Green AR, Walton DS, Kerin MJ, Fox JN, Carleton PJ, Desai SB & Atkin SL 1998 Short-term primary culture of epithelial cells derived from human breast tumours. British Journal of Cancer 78 1421-1429. (Pubitemid 28517537)
41. Spinola PG, Marchetti B, Mérand Y, Bélanger A & Labrie F 1988 Effects of the aromatase inhibitor 4-hydroxy-androstenedione and the antiandrogen flutamide on growth and steroid levels in DMBA-induced rat mammary tumors. Breast Cancer Research and Treatment 12 287-296.
42. Suzuki T, Moriya T, Ariga N, Kaneko C, Kanazawa M & Sasano H 2000 17beta-Hydroxysteroid dehydrogenase type 1 and type 2 in human breast carcinoma: a correlation to clinicopathological parameters. British Journal of Cancer 82 518-523. (Pubitemid 30085183)
43. Suzuki T, Darnel AD, Akahira JI, Ariga N, Ogawa S, Kaneko C, Takeyama J, Moriya T & Sasano H 2001 5alpha-Reductases in human breast carcinoma: possible modulator of in situ androgenic actions. Journal of Clinical Endocrinology and Metabolism 86 2250-2257.
44. Suzuki T, Miki Y, Nakata T, Shiotsu Y, Akinaga S, Inoue K, Ishida T, Kimura M, Moriya T & Sasano H 2003 Steroid sulfatase and estrogen sulfotransferase in normal human tissue and breast carcinoma. Journal of Steroid Biochemistry and Molecular Biology 86 449-454. (Pubitemid 37412583)
45. Suzuki T, Miki Y, Moriya T, Akahira J, Ishida T, Hirakawa H, Yamaguchi Y, Hayashi S & Sasano H 2007 5alpha-Reductase type 1 and aromatase in breast carcinoma as regulators of in situ androgen production. International Journal of Cancer 120 285-291.
46. Wang JH & Tuohimaa P 2007 Regulation of 17beta-hydroxysteroid dehydrogenase type 2, type 4 and type 5 by calcitriol, LXR agonist and 5alpha-dihydrotestosterone in human prostate cancer cells. Journal of Steroid Biochemistry and Molecular Biology 107 100-105.
47. Wu L, Einstein M, Geissler WM, Chan HK, Elliston KO & Andersson S 1993 Expression cloning and characterization of human 17 beta-hydroxysteroid dehydrogenase type 2, a microsomal enzyme possessing 20 alpha-hydroxysteroid dehydrogenase activity. Journal of Biological Chemistry 268 12964-12969. (Pubitemid 23182471)
48. Yamashita K, Okuyama M, Watanabe Y, Honma S, Kobayashi S & Numazawa M 2007 Highly sensitive determination of estrone and estradiol in human serum by liquid chromatography-electrospray ionization tandem mass spectrometry. Steroids 72 819-827.